Skip to main content

Table 1 Baseline information of SLE patients (n = 45)

From: PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus

Baseline characteristics ALL stable active NP-SLE P
n 45 15 15 15  
Age (years) 36.53 ± 13.54 38.00 ± 13.46 32.53 ± 11.60 39.07 ± 15.30 0.375
Female (n) 39 13 13 13  
Median SLEDAI (interquartile) 12.0 (3.0, 17.0) 2.0 (0,3.0) 12.0 (10.0,20.0) 15.0 (12.0,22.0) < 0.001
Laboratory tests
 Positive ANA (n) 45 15 15 15
 Positive anti-dsDNA (n) 28 8 9 11 0.516
Hypocomplementaemia (n) 24 6 7 10 0.315
 LDL-c (mmol/L) 2.85 ± 1.48 2.32 ± 0.86 3.02 ± 2.21 2.73 ± 1.33 0.478
 HDL-c (mmol/L) 1.12 ± 0.43 1.16 ± 0.39 1.37 ± 0.80 1.11 ± 0.43 0.416
 Triglycerides (mmol/L) 1.93 ± 1.20 1.53 ± 0.81 2.62 ± 1.70 1.76 ± 1.09 0.056
 Apo-A1 (g/L) 0.95 ± 0.31 1.04 ± 0.32 0.89 ± 0.27 0.98 ± 0.33 0.413
 Apo-B (g/L) 0.88 ± 0.38 0.69 ± 0.24 0.98 ± 0.43 0.89 ± 0.35 0.078
 SCr (μmol/L)
(interquartile)
59.0 (45.5104.5) 52.0 (45.0,59.0) 75.0 (50.0,153.0) 47.0 (66.0,107.0) 0.406
 eGFR(ml/min∙1.73m2)
(interquartile)
62.0 (50.0,85.8) 52.0 (45.0,58.0) 76.0 (54.0,120.0) 66.0 (58.3103.3) 0.055
 24-h urine protein (mg/L) (interquartile) 294.0 (86.0,1219.0) 170.0 (111.0,831.6) 568.0 (61.0,2126.0) 202.0 (471.0,5036.5) 0.646
 C3 (g/L)
(interquartile)
0.82 (0.59,1.03) 0.98 (0.86,1.10) 0.62 (0.46,9.00) 0.80 (0.52,1.01) 0.059
 C4 (g/L)
(interquartile)
0.16 (0.08,0.24) 0.19 (0.12,0.23) 0.10 (0.04,0.43) 0.15 (0.08,0.24) 0.372
Comorbidities
 Hypertension (n) 15 3 7 5 0.301
 Diabetes mellitus (n) 2 0 2 0 1.000
 Hyperlipidaemia (n) 9 4 4 1 0.235
 PAH (n) 8 2 3 3 0.854
Current medications
 Prednisone (n) 43 15 13 15 1.000
 Mycophenolate mofetil (n) 15 4 7 4 0.407
 Cyclophosphamide (n) 12 5 4 3 0.709
 Azathioprine (n) 6 2 3 1 0.549
 Hydrochloroquine (n) 44 15 14 15 1.000
 Cyclosporin/tacrolimus(n) 8 3 4 1 0.307
 ACE inhibitors/ARB (n) 28 8 10 10 0.685
  1. Normally distributed measurement data were shown as \( \overline{x} \) ± s, and analyzed by the F-test. Otherwise, they were expressed as P50 (P25, P75), and compared by the Bonferroni correction. Enumeration data were shown as n (%), and analyzed through the Chi-square test
  2. ANA, anti-nuclear antibody; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; Apo-A, apolipoprotein A; Apo-B, apolipoprotein B; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; PAH, pulmonary arterial hypertension; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker